When clinical outcomes are nearly equivalent, the critical questions become: How do we improve access, affordability, and long-term adherence
Ozempic has properties that help to control blood sugar levels and induce a feeling of fullness, leading to reduced calorie intake and helping with weight loss
Its just waste of money
The primary endpoint was percent change in body weight from baseline to 24 weeks, which resulted in a 17.5% reduction in the 12 mg (2 mg initial dose) group
up to 1.8%) and body weight compared with placebo and several active treatments, including sitagliptin, exenatide (extended-release), dulaglutide, and insulin glargine.In the SUSTAIN 6 trial, semaglutide also demonstrated CV safety and significantly reduced MACE compared with placebo, confirming its noninferiority while suggesting potential CV protection.[9] 5